nach oben

Current Cardiovascular Imaging Reports

Erschienen in:

01.02.2018 | Cardiac Nuclear Imaging (A Cuocolo and M Petretta, Section Editors)

Contemporary Advances in Myocardial Metabolic Imaging and Their Impact on Clinical Care: a Focus on Positron Emission Tomography (PET)

verfasst von: John P. Bois, Robert J. Gropler, Linda R. Peterson

Erschienen in: Current Cardiovascular Imaging Reports | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to give a brief historical context and overview of cardiac substrate metabolism, including recent discoveries, and then delve into newer advances in positron emission tomography (PET) myocardial metabolic imaging.

Recent Findings

Some of the recent discoveries of cardiac metabolism involve the pleiotropic effects of metabolism of minor substrates, such as ketones and branch chain amino acids. Contemporary advancements in cardiac imaging include the following: novel radiotracers, new technologies, and evidence showing how patient-specific attributes, such as sex and age, affect myocardial metabolism.

Summary

Myocardial metabolism is a dynamic field with several new advances. PET imaging has allowed us to better quantify and understand the complexities of the heart’s metabolism and the effects of different conditions and therapies on the heart, as well as detect potentially life-threatening infections in heart failure patients with left ventricular assist devices (LVADs).

Martins e Silva J. From the discovery of the circulation of the blood to the first steps in hemorheology: part 1. Rev Port Cardiol. 2009;28(11):1245–68.PubMed

Aird WC. Discovery of the cardiovascular system: from Galen to William Harvey. J Thromb Haemost. 2011;9(Suppl 1):118–29.CrossRefPubMed

Bing RJ. The course of science and cardiac metabolism. Circ Res. 1976;38(5 Suppl 1):I151–5.PubMed

Evans CL. The effect of glucose on the gaseous metabolism of the isolated mammalian heart. J Physiol. 1914;47(6):407–18. https://doi.org/10.1113/jphysiol.1914.sp001633.CrossRefPubMedPubMedCentral

Bing RJ, Siegel A, Ungar I, Gilbert M. Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. Am J Med. 1954;16(4):504–15.CrossRefPubMed

Mudge GH Jr, Mills RM Jr, Taegtmeyer H, Gorlin R, Lesch M. Alterations of myocardial amino acid metabolism in chronic ischemic heart disease. J Clin Invest. 1976;58(5):1185–92. https://doi.org/10.1172/JCI108571.CrossRefPubMedPubMedCentral

Shipp JC, Opie LH, Challoner D. Fatty acid and glucose metabolism in the perfused heart. Nature. 1961;189(4769):1018–9. https://doi.org/10.1038/1891018a0.CrossRef

Morgan HE, Henderson MJ, Regen DM, Park CR. Regulation of glucose uptake in muscle. I. The effects of insulin and anoxia on glucose transport and phosphorylation in the isolated, perfused heart of normal rats. J Biol Chem. 1961;236:253–61.PubMed

Roe CR, Sweetman L, Roe DS, David F, Brunengraber H. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest. 2002;110(2):259–69. https://doi.org/10.1172/JCI0215311.CrossRefPubMedPubMedCentral

10.

• Taegtmeyer H, Lam T, Davogustto G. Cardiac metabolism in perspective. Compr Physiol. 2016;6:1675–99. An excellent review of the principles of myocardial metabolism.CrossRefPubMed

11.

LH O. The heart: physiology, from cell to circulation. Philadelphia. 1998.

12.

Yuan CL, Sharma N, Gilge DA, et al. Preserved protein synthesis in the heart in response to acute fasting and chronic food restriction despite reductions in liver and skeletal muscle. Am J Physiol Endocrinol Metab. 2008;295:E216–22.CrossRefPubMedPubMedCentral

13.

Balaban RS. Cardiac energy metabolism homeostasis: role of cytosolic calcium. J Mol Cell Cardiol. 2002;34(10):1259–71. https://doi.org/10.1006/jmcc.2002.2082.CrossRefPubMed

14.

Balaban RS, Kantor HL, Katz LA, Briggs RW. Relation between work and phosphate metabolite in the in vivo paced mammalian heart. Science. 1986;232(4754):1121–3. https://doi.org/10.1126/science.3704638.CrossRefPubMed

15.

Kupriyanov VV, Lakomkin VL, Kapelko VI, Steinschneider A, Ruuge EK, Saks VA. Dissociation of adenosine triphosphate levels and contractile function in isovolumic hearts perfused with 2-deoxyglucose. J Mol Cell Cardiol. 1987;19(8):729–40. https://doi.org/10.1016/S0022-2828(87)80384-X.CrossRefPubMed

16.

Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr Probl Cardiol. 1994;19:59–113.CrossRefPubMed

17.

Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol. 2000;278(4):H1345–51. https://doi.org/10.1152/ajpheart.2000.278.4.H1345.CrossRefPubMed

18.

Neubauer S. The failing heart—an engine out of fuel. N Engl J Med. 2007;356(11):1140–51. https://doi.org/10.1056/NEJMra063052.CrossRefPubMed

19.

Baldwin JE, Krebs H. The evolution of metabolic cycles. Nature. 1981;291(5814):381–2. https://doi.org/10.1038/291381a0.CrossRefPubMed

20.

Olson RE. Myocardial metabolism in congestive heart failure. J Chronic Dis. 1959;9(5):442–64. https://doi.org/10.1016/0021-9681(59)90172-9.CrossRefPubMed

21.

Bing RJ. The metabolism of the heart. Harvey Lect. 1954;50:27–70.PubMed

22.

Bing RJ. Cardiac metabolism. Phsyiol Rev. 1965;45(2):171–213. https://doi.org/10.1152/physrev.1965.45.2.171.CrossRef

23.

Nagoshi T, Yoshimura M, Rosano GM, Lopaschuk GD, Mochizuki S. Optimization of cardiac metabolism in heart failure. Curr Pharm Des. 2011;17(35):3846–53. https://doi.org/10.2174/138161211798357773.CrossRefPubMedPubMedCentral

24.

Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340–50. https://doi.org/10.1161/CIRCULATIONAHA.107.739938.CrossRefPubMed

25.

Peterson LR, Soto PF, Herrero P, Mohammed BS, Avidan MS, Schechtman KB, et al. Impact of gender on the myocardial metabolic response to obesity. JACC Cardiovasc Imaging. 2008;1(4):424–33. https://doi.org/10.1016/j.jcmg.2008.05.004.CrossRefPubMedPubMedCentral

26.

Goodwin GW, Taylor CS, Taegtmeyer H. Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem. 1998;273(45):29530–9. https://doi.org/10.1074/jbc.273.45.29530.CrossRefPubMed

27.

Olson AL, Pessin JE. Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr. 1996;16(1):235–56. https://doi.org/10.1146/annurev.nu.16.070196.001315.CrossRefPubMed

28.

Doenst T, Taegtmeyer H. Alpha-adrenergic stimulation mediates glucose uptake through phosphatidylinositol 3-kinase in rat heart. Circ Res. 1999;84(4):467–74. https://doi.org/10.1161/01.RES.84.4.467.CrossRefPubMed

29.

•• Lopaschuk GD, Ussher JR. Evolving concepts of myocardial energy metabolism: more than just fats and carbohydrates. Circ Res. 2016;119:1173–6. This article reviews the use of myocardial substrates as signaling molecules, competition between different substrates for utilization, and substrate choice and cardiac efficiency.CrossRefPubMed

30.

Kaijser L, Lassers BW, Wahlqvist ML, Carlson LA. Myocardial lipid and carbohydrate metabolism in fasting men during prolonged exercise. J Appl Physiol. 1972;32(6):847–58. https://doi.org/10.1152/jappl.1972.32.6.847.CrossRefPubMed

31.

Gertz EW, Wisneski JA, Stanley WC, Neese RA. Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments. J Clin Invest. 1988;82(6):2017–25. https://doi.org/10.1172/JCI113822.CrossRefPubMedPubMedCentral

32.

Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol. 1974;36(1):413–59. https://doi.org/10.1146/annurev.ph.36.030174.002213.CrossRefPubMed

33.

Murray AJ, Knight NS, Cole MA, Cochlin LE, Carter E, Tchabanenko K, et al. Novel ketone diet enhances physical and cognitive performance. FASEB J. 2016;30(12):4021–32. https://doi.org/10.1096/fj.201600773R.CrossRefPubMedPubMedCentral

34.

• Zajac A, Poprzecki S, Maszczyk A, Czuba M, Michalczyk M, Zydek G. The effects of a ketogenic diet on exercise metabolism and physical performance in off-road cyclists. Nutrients. 2014;6:2493–508. This article demonstrates a proof-of-principle that ketone metabolism may be useful for enhancing overall performance in humans.CrossRefPubMedPubMedCentral

35.

Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2013;304(8):H1060–76. https://doi.org/10.1152/ajpheart.00646.2012.CrossRefPubMedPubMedCentral

36.

Muoio DM, Neufer PD. Lipid-induced mitochondrial stress and insulin action in muscle. Cell Metab. 2012;15(5):595–605. https://doi.org/10.1016/j.cmet.2012.04.010.CrossRefPubMedPubMedCentral

37.

•• Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab. 2014;25(1):42–52. This article reviews the effects of ketone bodies as signaling molecules in addition to their role as substrates. https://doi.org/10.1016/j.tem.2013.09.002.CrossRefPubMed

38.

Jewell JL, Russell RC, Guan KL. Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol. 2013;14(3):133–9. https://doi.org/10.1038/nrm3522.CrossRefPubMedPubMedCentral

39.

DeGrado TR, Bhattacharyya F, Pandey MK, Belanger AP, Wang S. Synthesis and preliminary evaluation of 18-(18)F-fluoro-4-thia-oleate as a PET probe of fatty acid oxidation. J Nucl Med. 2010;51(8):1310–7. https://doi.org/10.2967/jnumed.109.074245.CrossRefPubMed

40.

Tu Z, Li S, Sharp TL, Herrero P, Dence CS, Gropler RJ, et al. Synthesis and evaluation of 15-(4-(2-[(1)(8)F]fluoroethoxy)phenyl)pentadecanoic acid: a potential PET tracer for studying myocardial fatty acid metabolism. Bioconjug Chem. 2010;21(12):2313–9. https://doi.org/10.1021/bc100343h.CrossRefPubMedPubMedCentral

41.

O’Donnell JM, Fields AD, Sorokina N, Lewandowski ED. The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnover. J Mol Cell Cardiol. 2008;44(2):315–22. https://doi.org/10.1016/j.yjmcc.2007.11.006.CrossRefPubMed

42.

Saddik M, Lopaschuk GD. Triacylglycerol turnover in isolated working hearts of acutely diabetic rats. Can J Physiol Pharmacol. 1994;72(10):1110–9. https://doi.org/10.1139/y94-157.CrossRefPubMed

43.

Wicklmayr M, Rett K, Dietze G, Mehnert H. Inhibition of muscular triglyceride lipolysis by ketone bodies: a mechanism for energy-preservation in starvation. Horm Metab Res. 1986;18(07):476–8. https://doi.org/10.1055/s-2007-1012350.CrossRefPubMed

44.

Bucci M, Borra R, Nagren K, et al. Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans. Cardiovasc Ther. 2012;30:333–41.CrossRefPubMed

45.

Banke NH, Wende AR, Leone TC, et al. Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARalpha. Circ Res. 2010;107(2):233–41. https://doi.org/10.1161/CIRCRESAHA.110.221713.CrossRefPubMedPubMedCentral

46.

Labbe SM, Grenier-Larouche T, Noll C, et al. Increased myocardial uptake of dietary fatty acids linked to cardiac dysfunction in glucose-intolerant humans. Diabetes. 2012;61:2701–10.CrossRefPubMedPubMedCentral

47.

Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 2000;10(6):238–45. https://doi.org/10.1016/S1050-1738(00)00077-3.CrossRefPubMed

48.

Wang S, Fu C, Wang H, Shi Y, Xu X, Chen J, et al. Polymorphisms of the peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene are associated with hypertrophic cardiomyopathy and not with hypertension hypertrophy. Clin Chem Lab Med. 2007;45(8):962–7. https://doi.org/10.1515/CCLM.2007.189.CrossRefPubMed

49.

Djouadi F, Lecarpentier Y, Hebert JL, Charron P, Bastin J, Coirault C. A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Res. 2009;84(1):83–90. https://doi.org/10.1093/cvr/cvp183.CrossRefPubMed

50.

Solingapuram Sai KK, Kil KE, Tu Z, et al. Synthesis, radiolabeling and initial in vivo evaluation of [(11)C]KSM-01 for imaging PPAR-alpha receptors. Bioorg Med Chem Lett. 2012;22(19):6233–6. https://doi.org/10.1016/j.bmcl.2012.08.010.CrossRefPubMedPubMedCentral

51.

Lee H, Chen DL, Rothfuss JM, Welch MJ, Gropler RJ, Mach RH. Synthesis and evaluation of 18F-labeled PPARgamma antagonists. Nucl Med Biol. 2012;39(1):77–87. https://doi.org/10.1016/j.nucmedbio.2011.07.002.CrossRefPubMed

52.

Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57(4):660–71. https://doi.org/10.1007/s00125-014-3171-6.CrossRefPubMedPubMedCentral

53.

Zhou D, Lee H, Rothfuss JM, et al. Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fluoropropyl)-4-methyl-pyridin-2-amine as a potential PET tracer for inducible nitric oxide synthase. J Med Chem. 2009;52:2443–53.CrossRefPubMedPubMedCentral

54.

Herrero P, Laforest R, Shoghi K, et al. Feasibility and dosimetry studies for 18F-NOS as a potential PET radiopharmaceutical for inducible nitric oxide synthase in humans. J Nucl Med. 2012;53:994–1001.CrossRefPubMed

55.

Thorn SL, de Kemp RA, Dumouchel T, et al. Repeatable noninvasive measurement of mouse myocardial glucose uptake with 18F-FDG: evaluation of tracer kinetics in a type 1 diabetes model. J Nucl Med. 2013;54(9):1637–44. https://doi.org/10.2967/jnumed.112.110114.CrossRefPubMed

56.

Shoghi KI, Finck BN, Schechtman KB, Sharp T, Herrero P, Gropler RJ, et al. In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: differential efficacy of metformin and rosiglitazone monotherapy. Circ Cardiovasc Imaging. 2009;2(5):373–81. https://doi.org/10.1161/CIRCIMAGING.108.843227.CrossRefPubMedPubMedCentral

57.

Shoghi KI, Gropler RJ, Sharp T, Herrero P, Fettig N, Su Y, et al. Time course of alterations in myocardial glucose utilization in the Zucker diabetic fatty rat with correlation to gene expression of glucose transporters: a small-animal PET investigation. J Nucl Med. 2008;49(8):1320–7. https://doi.org/10.2967/jnumed.108.051672.CrossRefPubMedPubMedCentral

58.

Herrero P, Kim J, Sharp TL, et al. Assessment of myocardial blood flow using 15O-water and 1-11C-acetate in rats with small-animal PET. J Nucl Med. 2006;47:477–85.PubMed

59.

North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res. 2012;110(8):1097–108. https://doi.org/10.1161/CIRCRESAHA.111.246876.CrossRefPubMedPubMedCentral

60.

Maas AH, Appelman YE. Gender differences in coronary heart disease. Neth Heart J. 2010;18(12):598–602. https://doi.org/10.1007/s12471-010-0841-y.CrossRefPubMedPubMedCentral

61.

Peterson LR, Soto PF, Herrero P, Schechtman KB, Dence C, Gropler RJ. Sex differences in myocardial oxygen and glucose metabolism. J Nucl Cardiol. 2007;14(4):573–81. https://doi.org/10.1016/j.nuclcard.2007.03.001.CrossRefPubMedPubMedCentral

62.

Grist M, Wambolt RB, Bondy GP, English DR, Allard MF. Estrogen replacement stimulates fatty acid oxidation and impairs post-ischemic recovery of hearts from ovariectomized female rats. Can J Physiol Pharmacol. 2002;80(10):1001–7. https://doi.org/10.1139/y02-131.CrossRefPubMed

63.

Yoon M. The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions. Pharmacol Res. 2009;60(3):151–9. https://doi.org/10.1016/j.phrs.2009.02.004.CrossRefPubMed

64.

Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308(5728):1583–7. https://doi.org/10.1126/science.1112062.CrossRefPubMed

65.

McMillin JB, Taffet GE, Taegtmeyer H, Hudson EK, Tate CA. Mitochondrial metabolism and substrate competition in the aging Fischer rat heart. Cardiovasc Res. 1993;27(12):2222–8. https://doi.org/10.1093/cvr/27.12.2222.CrossRefPubMed

66.

Abu-Erreish GM, Neely JR, Whitmer JT, Whitman V, Sanadi DR. Fatty acid oxidation by isolated perfused working hearts of aged rats. Am J Phys. 1977;232:E258–62.

67.

van der Meer RW, Rijzewijk LJ, Diamant M, Hammer S, Schar M, Bax JJ, et al. The ageing male heart: myocardial triglyceride content as independent predictor of diastolic function. Eur Heart J. 2008;29(12):1516–22. https://doi.org/10.1093/eurheartj/ehn207.CrossRefPubMed

68.

Kakinuma Y, Okada S, Nogami M, Kumon Y. The human female heart incorporates glucose more efficiently than the male heart. Int J Cardiol. 2013;168(3):2518–21. https://doi.org/10.1016/j.ijcard.2013.03.016.CrossRefPubMed

69.

Wong CY, O'Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation. 2004;110(19):3081–7. https://doi.org/10.1161/01.CIR.0000147184.13872.0F.CrossRefPubMed

70.

Peterson LR, Herrero P, Schechtman KB, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004;109:2191–6.CrossRefPubMed

71.

Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C, et al. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol. 2006;47(3):598–604. https://doi.org/10.1016/j.jacc.2005.09.030.CrossRefPubMed

72.

Listenberger LL, Ory DS, Schaffer JE. Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J Biol Chem. 2001;276(18):14890–5. https://doi.org/10.1074/jbc.M010286200.CrossRefPubMed

73.

Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A. 2000;97:1784–9.CrossRefPubMedPubMedCentral

74.

Lin CH, Kurup S, Herrero P, Schechtman KB, Eagon JC, Klein S, et al. Myocardial oxygen consumption change predicts left ventricular relaxation improvement in obese humans after weight loss. Obesity (Silver Spring). 2011;19(9):1804–12. https://doi.org/10.1038/oby.2011.186.CrossRef

75.

Mikhalkova, D HS, Jiang H, Saghir M, Novak E, Coggan AR, O’Connor R, Bashir A, Jamal A, Ory DS, Schaffer JE, Eagon JC, Peterson LR. Bariatric surgery-induced cardiac and lipidomic changes in obesity-related heart failure with preserved ejection fraction. Obesity 2017 (in press).

76.

Lyons MR, Peterson LR, McGill JB, Herrero P, Coggan AR, Saeed IM, et al. Impact of sex on the heart's metabolic and functional responses to diabetic therapies. Am J Physiol Heart Circ Physiol. 2013;305(11):H1584–91. https://doi.org/10.1152/ajpheart.00420.2013.CrossRefPubMedPubMedCentral

77.

Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245. https://doi.org/10.1161/CIR.0b013e31828124ad.CrossRefPubMed

78.

Razeghi P, Young ME, Cockrill TC, Frazier OH, Taegtmeyer H. Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure. Circulation. 2002;106(4):407–11. https://doi.org/10.1161/01.CIR.0000026392.80723.DC.CrossRefPubMed

79.

Buttrick PM, Kaplan M, Leinwand LA, Scheuer J. Alterations in gene expression in the rat heart after chronic pathological and physiological loads. J Mol Cell Cardiol. 1994;26(1):61–7. https://doi.org/10.1006/jmcc.1994.1008.CrossRefPubMed

80.

Tuunanen H, Engblom E, Naum A, et al. Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail. 2006;12:644–52.CrossRefPubMed

81.

Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004;18(14):1692–700. https://doi.org/10.1096/fj.04-2263com.CrossRefPubMed

82.

Davila-Roman VG, Vedala G, Herrero P, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002;40:271–7.CrossRefPubMed

83.

Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996;137(7):2968–78. https://doi.org/10.1210/endo.137.7.8770921.CrossRefPubMed

84.

Blackmore PF, Mojsov S, Exton JH, Habener JF. Absence of insulinotropic glucagon-like peptide-I(7-37) receptors on isolated rat liver hepatocytes. FEBS Lett. 1991;283(1):7–10. https://doi.org/10.1016/0014-5793(91)80541-A.CrossRefPubMed

85.

Yamato E, Ikegami H, Takekawa K, et al. Tissue-specific and glucose-dependent expression of receptor genes for glucagon and glucagon-like peptide-1 (GLP-1). Horm Metab Res. 1997;29:56–9.CrossRefPubMed

86.

Zhao T, Parikh P, Bhashyam S, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006;317:1106–13.CrossRefPubMed

87.

Bhashyam S, Fields AV, Patterson B, Testani JM, Chen L, Shen Y, et al. Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail. 2010;3(4):512–21. https://doi.org/10.1161/CIRCHEARTFAILURE.109.900282.CrossRefPubMedPubMedCentral

88.

Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110:955–61.CrossRefPubMed

89.

Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58(4):975–83. https://doi.org/10.2337/db08-1193.CrossRefPubMedPubMedCentral

90.

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. https://doi.org/10.1056/NEJMoa1603827.CrossRefPubMedPubMedCentral

91.

Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19:69–77.CrossRefPubMed

92.

Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of Liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500–8. https://doi.org/10.1001/jama.2016.10260.CrossRefPubMedPubMedCentral

93.

Tuunanen H, Engblom E, Naum A, et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation. 2006;114:2130–7.CrossRefPubMed

94.

•• Kadkhodayan A, Lin CH, Coggan AR, et al. Sex affects myocardial blood flow and fatty acid substrate metabolism in humans with nonischemic heart failure. J Nucl Cardiol 2016. This article demonstrated that there is a sex-related difference in myocardial metabolism in patients with heart failure with reduced ejection fraction. Women with heart failure had less of a “shift” in metabolism away from fatty acids and towards glucose.

95.

•• Kim J, Feller ED, Chen W, Dilsizian V. FDG PET/CT imaging for LVAD associated infections. JACC Cardiovasc Imaging. 2014;7:839–42. This article depicts how PET/CT imaging is clinically useful for identifying and localizing highly morbid LVAD infections.CrossRefPubMed

96.

•• Taegtmeyer H, Karlstaedt A, Rees ML, Davogustto G. Oncometabolic tracks in the heart. Circ Res. 2017;120:267–9. This article discusses the consequences of metabolic dysregulation in cancer on the heart’s metabolism and function.CrossRefPubMed

97.

Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225–34.CrossRefPubMedPubMedCentral

98.

Karlstaedt A, Zhang X, Vitrac H, et al. Oncometabolite d-2-hydroxyglutarate impairs alpha-ketoglutarate dehydrogenase and contractile function in rodent heart. Proc Natl Acad Sci U S A. 2016;113:10436–41.CrossRefPubMedPubMedCentral

Titel: Contemporary Advances in Myocardial Metabolic Imaging and Their Impact on Clinical Care: a Focus on Positron Emission Tomography (PET)
verfasst von: John P. Bois
Robert J. Gropler
Linda R. Peterson
Publikationsdatum: 01.02.2018
Verlag: Springer US
Erschienen in: Current Cardiovascular Imaging Reports / Ausgabe 2/2018
Print ISSN: 1941-9066
Elektronische ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-018-9444-6

Neu im Fachgebiet Kardiologie

19.04.2024 | Vorhofflimmern | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Contemporary Advances in Myocardial Metabolic Imaging and Their Impact on Clinical Care: a Focus on Positron Emission Tomography (PET)

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie